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Abstract Red cell distribution width (RDW), a measure of variability in size of circulating
erythrocytes, is associated with arterial cardiovascular disease (CVD), but the under-
lying mechanism remains unclear. We aimed to investigate the impact of chronic
inﬂammation as measured by high-sensitivity C-reactive protein (hs-CRP) on this
relationship, and explore whether RDW could be a mediator in the causal pathway
between inﬂammation and arterial CVD. Baseline characteristics, including RDW and
hs-CRP, were obtained from 5,765 individuals attending a population-based cohort
study. We followed up participants from inclusion in the fourth survey of the Tromsø
Study (1994/1995) until December 31, 2012. Multivariable Cox-regression models
were used to calculate hazard ratios (HR) with 95% conﬁdence intervals (CI) for incident
myocardial infarction (MI) and ischemic stroke across quintiles of hs-CRP and RDW.
Subjects with hs-CRP in the highest quintile had 44% higher risk of MI (HR: 1.44, 95% CI:
1.14–1.80), and 64% higher risk of ischemic stroke (HR: 1.64, 95% CI: 1.20–2.24)
comparedwith subjects in the lowest quintile. RDWmediated 7.2% (95% CI: 4.0–30.8%)
of the association between hs-CRP and ischemic stroke. Subjects with RDW in the
highest quintile had 22% higher risk of MI (HR: 1.22, 95% CI: 0.98–1.54) and 44% higher
risk of ischemic stroke (HR: 1.44, 95% CI: 1.06–1.97) compared with subjects in the
lowest quintile. These risk estimates were slightly attenuated after adjustments for hs-
CRP. Our ﬁndings suggest that chronic inﬂammation is not a primary mechanism
underlying the relationship between RDW and arterial CVD.
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Introduction
Red blood cell distribution width (RDW) is a measure of the
variability in size of circulating erythrocytes, and is reported
bymost automated blood cell counters.1 In combinationwith
mean corpuscular volume (MCV), RDW has traditionally
been used in the differential diagnosis of anemia.2 Various
causes of premature release of red blood cells may lead to
alterations in the RDW.3–5
Growing evidence supports a relationship between RDW
and arterial cardiovascular disease (CVD). In two large
population-based cohorts, RDW was associated with future
risk of incident MI6,7 and ischemic stroke.8,9 However, the
mechanisms behind these relationships are not clear.
Atherosclerosis, the principle cause of myocardial infarc-
tion (MI) and an important cause of ischemic stroke,10 is
widely recognized as an inﬂammatory disease.11,12 C-reac-
tive protein (CRP), an acute phase reactant synthesized in
response to signals from macrophages and T cells during
inﬂammation (e.g., interleukin-6),13 is a predictor of MI and
stroke.14–17 Inﬂammation affects red blood cell life span and
modulates the effect of erythropoietin on the erythropoiesis,
and can thereby affect RDW.18 Studies have reported an
association between RDW and CRP, erythrocyte sedimenta-
tion rate (ESR), and interleukin-6.19–22
Since chronic inﬂammation is associated with increased
risk of arterial CVD, and RDW is associated with several
markers of chronic inﬂammation, it has been hypothesized
that the apparent association between RDW and risk of
arterial CVD could be explained by chronic inﬂammation.
On one hand, chronic inﬂammation could merely serve as a
confounder for the relationship between RDW and arterial
CVD (►Fig. 1A). Alternatively, if RDW is causally associated
with arterial CVD (e.g., through mechanisms of augmented
erythrocyte aggregability or altered blood viscosity), it could
act as mediator in the pathway between chronic inﬂamma-
tion and CVD (►Fig. 1B).
Despite the indications that chronic inﬂammation may
inﬂuence the association between RDW and arterial CVD,
this hypothesis has not been thoroughly investigated. There-
fore, we set out to study whether the association between
RDW and arterial CVD was confounded by chronic inﬂam-
mation (assessed by hs-CRP), or whether chronic inﬂamma-
tion was associated with changes in RDW (mediator) that
directly could lead to increased risk of arterial CVD.
Materials and Methods
Study Population
The fourth survey of the Tromsø study (Tromsø 4) was
conducted in 1994–1995, and all inhabitants in the munici-
pality of Tromsø, Norway, aged 25 or older, were invited to
participate. A total of 27,158 individuals attended the ﬁrst
visit, yielding a participation rate of 77%. Following this, all
participants aged 55 to 74 years, as well as 5 to 8% randomly
selected samples from each of the other 5-year age intervals
(between 25–54 years and 75–85 years), were offered a
follow-up visit (1994–1995). At this second visit, the parti-
cipants underwent a more thorough examination, and addi-
tional measurements including high-sensitivity CRP (hs-
CRP) were performed. All subjects attending the second visit
of Tromsø 4 were enrolled in the present study (n ¼ 6,834;
76% of those eligible). The study population has been
described in detail elsewhere.23 We excluded subjects lack-
ing measurements of RDW (n ¼ 169) and hs-CRP (n ¼ 118),
subjects with a diagnosis of MI (n ¼ 354) or stroke (n ¼ 166)
prior to enrolment, as well as subjects migrating from
Tromsø before the second visit (n ¼ 7). In addition, we
excluded participants with hs-CRP levels >10 mg/L
(n ¼ 255) at baseline to avoid inﬂuence of possible acute
phase reactions. This left us with 5,765 participants in the
present study. The Regional Committee for Medical and
Health Research Ethics approved the study, and informed
written consent was acquired from all participants.
Baseline Measurements
Baseline information on each participant was obtained
through self-administered questionnaires, blood samples,
and physical examinations. Nonfasting blood samples were
drawn from an antecubital vein into vacutainer tubes con-
taining EDTA for anticoagulation (K3-EDTA 40 µL, 0.37 mol/L
per tube). For the blood cell counts, including RDW, 5 mL of
blood was analyzed within 12 hours in an automated blood
cell counter (Coulter Counter; Coulter Electronics, Luton,
UK). RDW was calculated by dividing the standard deviation
(SD) of MCV with the MCV, then multiplying it by 100.24 For
preparation of serum, the blood sample was given a 1-hour
Fig. 1 Potential associations between chronic inﬂammation, red cell
distribution width (RDW), and risk of cardiovascular disease (CVD).
(A) Illustration of how chronic inﬂammation could act as a confounder
of the association, affecting both RDWand risk of CVD. (B) Illustration
of how RDW could act as a mediator in the causal pathway between
chronic inﬂammation and arterial CVD.
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respite at room temperature before centrifugation. Hs-CRP
wasmeasured by a particle-enhanced immunoturbidimetric
assay on a Modular P auto-analyzer (Roche/Hitachi) using
reagents from Roche Diagnostics GmbH, Mannheim, Ger-
many. The lower detection limit for the assay was 0.03 mg/L,
and all measurements below this threshold were set to 0.03
mg/L. Daily changes in the assay precision for values between
0.1 and 20 mg/L were less than 4%.
Trained personnel recorded blood pressure on the right
upper arm with an automatic device (Dinamap Vital Signs
Monitor; 1846, Critikon Inc., Tampa, Florida, United States).
Starting with 2 minutes of rest in a seated position, three
recordings with 2-minute intervals were completed. The
mean value of the last two recordingswas used in this article.
Hypertension was deﬁned as a systolic blood pressure
140 mm Hg, diastolic blood pressure 90 mm Hg, or
current use of antihypertensive medication. Measurements
of height andweight were performed using electronic scales,
with participants wearing no shoes and light clothing. The
bodymass index (BMI) was calculated by dividing theweight
in kilograms by the square of height in meters.
Information on diabetes and smoking was obtained from
the questionnaires. The question on diabetes was stated as
follows: “do you have or have you had diabetes?” (yes/no).
Subjectswere deﬁned as non-smokers only if answering “no”
to all three of the following questions: “do you smoke
cigarettes daily?”; “do you smoke cigars/cigarillos daily?”;
or “do you smoke pipe daily?” Study participants answering
“yes” to any of the three were deﬁned as daily smokers.
Outcome Assessment
All ﬁrst-time events of MI and ischemic stroke were identiﬁed
by searching a wide range of International Classiﬁcation of
Disease (ICD) codes at theUniversity Hospital of North Norway
and the National Causes of Death Registry at Statistics Norway.
The Norwegian national 11-digit identiﬁcation number
allowed linkage to both diagnosis and death registries. The
UniversityHospitalofNorthNorway is theonlyhospital serving
the municipality of Tromsø, and the next nearest hospital is
around 250 km away. This ensured that very few cases were
lost during follow-up. An independent endpoint committee
validated all stroke and MI events by retrieval of hospital
medical records, death certiﬁcates, autopsy reports, and
records from nursing homes, ambulance services, and general
practitioners. The thorough process of identiﬁcation and vali-
dation of outcomes has been previously described in detail.6,9
Statistical Analyses
Statistical analyses were performedwith STATA version 14.0
(StataCorp LLC, College Station, Texas, United States). Follow-
up timewas calculated from the date of enrolment in Tromsø
4 (1994–1995) to the date of a stroke or MI event, date of
death, date of migration from Tromsø, or until the end of
follow-up (December 31, 2012), whichever cameﬁrst. A total
of 115 subjects experienced both outcomes during follow-
up, and were censored from the ﬁrst occurring event.
The study populationwas categorized into quintiles accord-
ing to theirbaselineRDWvalues (Quintile1:12.4%,Quintile2:
12.5–12.8%, Quintile 3: 12.9–13.1%, Quintile 4: 13.2–13.5%,
Quintile 5: 13.6%) and their baseline hs-CRP values (Quintile
1: 0.01–0.51mg/L,Quintile 2:0.52–0.88mg/L,Quintile3: 0.89–
1.47 mg/L, Quintile 4: 1.48–2.68 mg/L, Quintile 5: 2.69–9.97
mg/L). Age-adjusted baseline characteristics across quintiles
ofRDWandhs-CRPwereestimatedusinganalysisofcovariance
(ANCOVA). The correlation between RDW and hs-CRP was
evaluated by calculating crude Pearson’s correlation
coefﬁcients.
Crude incidence rates (IRs) were calculated as the total
number of events divided by the total person time, and
expressed as number of events per 1,000 person-years at
risk. Cox proportional hazard regression models were used to
estimate hazard ratios (HRs)with 95% conﬁdence intervals (CI)
forMI and ischemic stroke across quintiles of RDWand hs-CRP,
and per 1 SD increment in RDW (0.8%) and hs-CRP (1.69mg/L).
Subjects in Quintile 1 of each exposure group were used as
reference in thecategorical analyses.Agewasusedas timescale
in the regression analyses. The multivariable analyses were
divided into three different models. Model 1 included adjust-
ments for age (through the time scale), sex, and BMI. Model 2
included the covariates in model 1, in addition to smoking
status, platelet count, hypertension, total cholesterol, triglycer-
ides, and self-reported diabetes. In the analyses across quintiles
of RDW, hs-CRP was added as a covariate to adjustment model
2, to evaluate whether chronic inﬂammation confounded the
association between RDW and the CVD outcomes. In the
analyses across quintiles of hs-CRP, baseline RDW values
were added to adjustment model 2, to evaluate the potential
mediating role of RDW. Furthermore,mediation analyseswere
conducted to calculate the proportion of the total exposure–
outcome effect that could be due to the mediator.25
Results
There were 913 incident MIs (IR: 11.5 per 1,000 person-
years, 95% CI: 10.7–12.2) and 461 incident ischemic stroke
events (IR: 5.8 per 1,000 person-years, 95% CI: 5.3–6.3)
during a median follow-up of 17.6 years. ►Table 1 shows
crude baseline characteristics according to subjects who
experienced MI, subjects who experienced ischemic stroke,
and those who remained free of arterial CVD throughout the
study period. The proportion of men, subjects with diabetes
and hypertension, as well as age, levels of triglycerides, RDW,
hs-CRP, hemoglobin, and BMI were all higher in those with
than those without arterial CVD. The proportion of smokers
was higher among those suffering an MI, but not among
those with ischemic stroke. The crude correlation analysis
revealed a low, but statistically signiﬁcant correlation coefﬁ-
cient between hs-CRP and RDW (r ¼ 0.13, p < 0.0001). Age-
adjusted baseline characteristics across quintiles of RDWand
hs-CRP are shown in ►Supplementary Table S1.
►Table 2 displays IRs and HRs for MI and ischemic stroke
across quintiles of hs-CRP. The crude IRs of both MI and
ischemic stroke increased with increasing serum concentra-
tions of hs-CRP. In multivariable-adjusted analyses, subjects
with hs-CRP in the upper quintile had a 44% higher risk of MI
(model 2, HR: 1.44, 95% CI: 1.14–1.80) and 64% higher risk of
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ischemic stroke (model 2, HR: 1.64, 95% CI: 1.20–2.24)
compared with subjects with hs-CRP in the lowest quintile.
The risk estimate for MI was essentially unchanged after
including RDW in the adjustment model (model 3, HR: 1.42,
95% CI: 1.13–1.78), whereas the risk estimate for ischemic
stroke was modestly attenuated (model 3, HR: 1.59, 95% CI:
1.16–2.17). In mediation analyses, RDW was estimated to
mediate 7.2% (95% CI: 4.0–30.8%) of the total association
between hs-CRP and ischemic stroke. The association
between hs-CRP and MI was not mediated by RDW (0.6%,
95% CI: 1.4 to 4.3%). In the analysis of CRP as a continuous
variable, 1 SD (1.69 mg/L) increase in hs-CRP was associated
with an 8% higher risk of MI (model 2, HR: 1.08, 95% CI: 1.04–
1.12) and an 11% higher risk of ischemic stroke (model 2, HR:
1.11, 95% CI: 1.06–1.16).
HRs and IRs for MI and ischemic stroke across quintiles of
RDW are shown in ►Table 3. In the multivariable model,
subjects with RDW values in the highest quintile had a 22%
higher risk of MI (HR: 1.22, 95% CI: 0.98–1.54) and a 44%
higher risk of ischemic stroke (HR: 1.44, 95% CI: 1.06–1.97)
comparedwith the reference group. After addition of hs-CRP
to themultivariable analyses, the risk estimateswere slightly
attenuated for both outcomes, with a HR for MI of 1.17
(model 3, 95% CI: 0.93–1.47), and a HR for ischemic stroke
of 1.37 (model 3, 95% CI: 1.00–1.87). When modeled as a
continuous variable, a 1 SD increase (0.8%) in RDW was
associatedwith a 6% higher risk ofMI (model 2, HR: 1.06, 95%
CI: 0.99–1.14) and a 14% higher risk of ischemic stroke
(model 2, HR: 1.14, 95% CI: 1.05–1.24). These risk estimates
were also slightly attenuated by adding hs-CRP to the multi-
variable analysis (model 3).
Discussion
In the present study, we explored the impact of chronic
inﬂammation on the association between RDW and arterial
CVD in a prospective, population-based cohort. RDW was
associated with higher risks of MI and ischemic stroke, and
these risk estimates were only modestly affected by adjust-
ment for hs-CRP. Hs-CRP was associatedwithMI and ischemic
stroke independent of other traditional atherosclerotic risk
factors. Addition of RDW to the multivariable models slightly
attenuated the association between hs-CRP and ischemic
stroke, and speciﬁc mediation analyses indicated a modest
role of RDW in mediating this relationship. Our ﬁndings
suggest that chronic inﬂammation had only a modest impact
on the relationship between RDW and arterial CVD.
CRP is a well-documented risk factor for arterial CVD. In a
meta-analysis of 54 long-term prospective studies including
160,309 subjects without previous vascular disease, the risk
ratio per 1 SD increase in CRP was 1.37 for coronary heart
disease, and 1.27 for ischemic stroke.17 Accordingly, we
found an association between hs-CRP and both MI and
ischemic stroke in our study. Furthermore, our results also
concurred with most previous studies on the relationship
between RDW and arterial CVD. In the Malmö Diet and
Cancer study, a cohort with RDW measurements of 26,879
participants, Söderholm et al found a 30% higher risk of
cerebral infarction for those in the highest versus the lowest
RDW quartile.8 In the same cohort, subjects in the highest
RDWquartile had an 82% higher risk of fatal coronary events,
but not increased risk of nonfatal coronary events (HR: 0.96,
95% CI: 0.82–1.12), compared with those in the lowest
quartile.7 In previous studies using the phase 1 population
from Tromsø 4 (n > 26,000), subjects with RDW in the
highest quintile had 30% higher risk of ischemic stroke,9
and 34% higher risk of MI compared with subjects in the
lowest quintile.6 Results from a prospective study on 3,226
previously healthy subjects from Taiwan,26 however,
reported no relationship between RDW and incident MI.
Several studies have reported a relationship between
various markers of inﬂammation and RDW. Chronic diseases
and inﬂammation affect the erythropoiesis and modulate
red cell life span, and can thereby cause changes in the
RDW.18 In a cohort of 3,845 adult outpatients, Lippi et al
found a threefold higher ESR and CRP in subjects with
RDW in the highest compared with the lowest quartile.19
A correlation between serum levels of CRP and RDW has
been described in patients with non-dipper hypertension
(r ¼ 0.403, p < 0.001),27 patients with coronary artery dis-
ease (r ¼ 0.181, p < 0.001),22 and in overweight adolescents
Table 1 Baseline characteristics stratiﬁed according to future
development of myocardial infarction or ischemic stroke
(The Tromsø Study)
No event Myocardial
infarction
Ischemic
stroke
N 4,506 913 461
RDW, % 13.0  0.8 13.1  0.8 13.2  1.0
hs-CRP, mg/L 1.67  1.69 2.11  1.90 2.17  1.86
Age, y 58.4  10.5 63.8  7.5 65.3  6.8
Sex, % males 44.4 (2001) 59.5 (543) 53.8 (248)
Body mass
index kg/m2
25.7  3.9 26.6  4.1 26.4  3.9
Daily smoking, % 32.0 (1,440) 38.2 (349) 31.0 (143)
Hemoglobin
(total), g/dL
14.1  1.1 14.4  1.0 14.3  1.1
Thrombocytes,
109/L
248  56 246  56 247  55
Hypertension, % 50.8 (2,288) 72.8 (665) 77.2 (356)
Total cholesterol,
mmol/L
6.7  1.3 7.0  1.2 6.8  1.3
Triglycerides,
mmol/L
1.6  1.0 1.9  1.1 1.8  1.0
Red blood cells,
1012/L
4.6  0.4 4.7  0.4 4.7  0.4
Self-reported
diabetes, %
1.9 (85) 5.6 (51) 6.5 (30)
Abbreviations: hs-CRP, high-sensitivity C-reactive protein; RDW, red cell
distribution width.
Note: Baseline characteristics of study participants stratiﬁed according
to future development of myocardial infarction or ischemic stroke. The
values are reported as means  standard deviation or as percentages
with number in brackets.
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Table 2 Adjusted HRs for myocardial infarction and ischemic stroke according to categories of hs-CRP (The Tromsø Study)
hs-CRP Events Crude IR
(95% CI)
Age/Sex-adjusted
HR (95% CI)
Model 1
HR (95% CI)
Model 2
HR (95% CI)
Model 3
HR (95% CI)
Myocardial infarction
Q1 126 7.2 (6.0–8.6) Ref. Ref. Ref. Ref.
Q2 153 9.3 (8.0–10.9) 1.08 (0.85–1.36) 1.05 (0.83–1.33) 0.97 (0.77–1.24) 0.97 (0.76–1.23)
Q3 195 12.0 (10.4–13.8) 1.33 (1.06–1.67) 1.26 (1.00–1.58) 1.11 (0.88–1.39) 1.10 (0.87–1.39)
Q4 196 12.6 (10.9–14.5) 1.39 (1.11–1.74) 1.30 (1.04–1.63) 1.10 (0.87–1.39) 1.09 (0.86–1.38)
Q5 243 17.4 (15.4–19.8) 1.94 (1.56–2.40) 1.81 (1.45–2.25) 1.44 (1.14–1.80) 1.42 (1.13–1.78)
Per 1 SD
increase
913 11.5 (10.7–12.2) 1.12 (1.09–1.16) 1.11 (1.08–1.15) 1.08 (1.04–1.12) 1.08 (1.04–1.11)
Ischemic stroke
Q1 65 3.7 (2.9–4.7) Ref. Ref. Ref. Ref.
Q2 73 4.4 (3.5–5.6) 0.98 (0.70–1.37) 0.96 (0.69–1.35) 0.87 (0.62–1.23) 0.87 (0.62–1.22)
Q3 90 5.5 (4.5–6.8) 1.15 (0.84–1.59) 1.12 (0.81–1.55) 1.00 (0.72–1.38) 0.99 (0.71–1.37)
Q4 97 6.2 (5.1–7.6) 1.31 (0.95–1.79) 1.27 (0.92–1.74) 1.13 (0.82–1.57) 1.11 (0.80–1.54)
Q5 136 9.8 (8.2–11.5) 2.06 (1.53–2.77) 2.00 (1.48–2.70) 1.64 (1.20–2.24) 1.59 (1.16–2.17)
Per 1 SD
increase
461 5.8 (5.3–6.3) 1.14 (1.09–1.19) 1.14 (1.09–1.19) 1.11 (1.06–1.16) 1.10 (1.05–1.16)
Abbreviations: BMI, body mass index; CI, conﬁdence interval; hs-CRP, high-sensitivity C-reactive protein; HR, hazard ratio; IR, incidence rate;
RDW, red cell distribution width; SD, standard deviation.
Notes:
Model 1: Age, sex, BMI.
Model 2: Model 1 þ smoking, platelet count, hypertension, total cholesterol, triglycerides, self-reported diabetes.
Model 3: Model 2 þ RDW.
IRs per 1,000 person-years and adjusted HRs with 95% CI for myocardial infarction and ischemic stroke across quintiles of hs-CRP, and per 1 SD
increase in hs-CRP.
Table 3 Adjusted HRs for myocardial infarction and ischemic stroke according to categories of RDW (The Tromsø Study)
RDW Events Crude IR
(95% CI)
Age/Sex-adjusted
HR (95% CI)
Model 1
HR (95% CI)
Model 2
HR (95% CI)
Model 3
HR (95% CI)
Myocardial infarction
Q1 138 8.0 (6.8–9.4) Ref. Ref. Ref. Ref.
Q2 198 9.5 (8.2–10.9) 1.01 (0.81–1.25) 1.00 (0.80–1.24) 0.99 (0.79–1.24) 0.98 (0.79–1.23)
Q3 184 12.6 (10.9–14.6) 1.23 (0.99–1.54) 1.22 (0.98–1.53) 1.19 (0.95–1.49) 1.18 (0.94–1.47)
Q4 190 13.8 (12.0–15.9) 1.30 (1.04–1.62) 1.29 (1.04–1.61) 1.22 (0.97–1.53) 1.20 (0.95–1.50)
Q5 203 15.4 (13.4–17.6) 1.41 (1.13–1.75) 1.40 (1.13–1.74) 1.22 (0.98–1.54) 1.17 (0.93–1.47)
Per 1 SD
increase
913 11.5 (10.7–12.2) 1.11 (1.04–1.18) 1.11 (1.04–1.18) 1.06 (0.99–1.14) 1.04 (0.97–1.12)
Ischemic stroke
Q1 70 4.0 (3.2–5.1) Ref. Ref. Ref Ref.
Q2 97 4.6 (3.8–5.7) 0.97 (0.71–1.32) 0.95 (0.70–1.30) 0.98 (0.71–1.33) 0.97 (0.71–1.32)
Q3 86 5.9 (4.8–7.3) 1.11 (0.81–1.53) 1.11 (0.81–1.52) 1.12 (0.81–1.54) 1.11 (0.80–1.53)
Q4 89 6.5 (5.3–8.0) 1.17 (0.86–1.61) 1.18 (0.86–1.61) 1.22 (0.88–1.69) 1.19 (0.86–1.64)
Q5 119 9.0 (7.5–10.8) 1.57 (1.17–2.11) 1.57 (1.16–2.11) 1.44 (1.06–1.97) 1.37 (1.00–1.87)
Per 1 SD
increase
461 5.8 (5.3–6.3) 1.17 (1.09–1.26) 1.18 (1.09–1.27) 1.14 (1.05–1.24) 1.11 (1.03–1.21)
Abbreviations: BMI, body mass index; CI, conﬁdence interval; hs-CRP, high-sensitivity C-reactive protein; HR, hazard ratio; IR, incidence rate;
RDW, red cell distribution width; SD, standard deviation.
Notes:
Model 1: Age, sex, BMI.
Model 2: Model 1 þ smoking, platelet count, hypertension, total cholesterol, triglycerides, self-reported diabetes.
Model 3: Model 2 þ hs-CRP.
IRsper 1,000person-years andadjustedHRswith95%CI formyocardial infarctionand ischemic strokeacross quintiles ofRDW,andper 1 SD increase inRDW.
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(r ¼ 0.241, p ¼ 0.034).28 In patients with Alzheimer’s dis-
ease, both CRP (r ¼ 0.350, p < 0.001) and ESR (r ¼ 0.457,
p < 0.001) correlated with RDW.29
Previously, only a few studies have investigated the
potential impact of chronic inﬂammation as a confounder
of the relationship between RDW and adverse outcomes. In
the Malmö Diet and Cancer study, the association between
RDW and fatal coronary events remained unchanged after
addition of leukocyte count to the multivariable analyses.7
Similarly, the association between RDWand heart failure did
not change after adjustments for CRP in a large prospective
study,30 and a 1% increment in RDW yielded equal risk of all-
cause mortality independent of hs-CRP levels.31
Our ﬁndings undermine thehypothesis that chronic inﬂam-
mation is the main explanation for the observed relationship
between RDW and risk of arterial CVD. First, RDW and hs-CRP
levels were weakly correlated in our population. Second, the
relationshipbetweenRDWand arterial CVDwasonlymodestly
affected by adding hs-CRP to the multivariable analyses. How-
ever, residual confounding by inﬂammation cannot be com-
pletely ruled out, as our measurements of hs-CRP might not
sufﬁciently reﬂect a chronic inﬂammatory state. Nevertheless,
if the effect of RDW on arterial CVD is indirect, residual
confounding by a factor other than inﬂammation seems
more plausible in the light of our ﬁndings. Oxidative stress,
stimulated by common cardiovascular risk factors, plays a
crucial role in the pathogenesis of atherosclerosis.32,33 Oxida-
tive stress is also an important regulator of hematopoietic cell
homeostasis, and could thereby inﬂuence RDW and confound
the relationship between RDW and arterial CVD.34 Unfortu-
nately, we do not have measurements of reactive oxygen
species in our population, and we were unable to adjust for
this potential confounder. Anemia, shown to be a risk factor for
CVD,35 could also potentially confound the association, as it is
clearly linked to RDW. However, several prospective studies,
including previous analyses of the Tromsø study, have shown
that the association between RDW and arterial CVD is inde-
pendent of anemia.6,8,9,36
A direct relationship between erythrocyte size variability
and arterial CVD may be biologically plausible. Erythrocytes
play an important role in atherosclerotic plaque develop-
ment and stability. Deposition of the free cholesterol con-
tained in the erythrocyte membrane is considered an
important contributor to atherosclerotic plaque growth,37,38
and atherosclerotic plaques susceptible to rupture tend to
have a higher lipid content than stable plaques.39 RDW is
associated with a higher cholesterol content in the erythro-
cyte membranes,40 and intraplaque hemorrhage could
thereby have a greater impact on plaque growth and instabil-
ity in subjects with high RDW. Furthermore, RDW is asso-
ciated with reduced red cell deformability,41 which again is
linked to increased aggregation of erythrocytes, altered
blood viscosity, and impaired blood ﬂow in the microcircu-
lation.42–44 RDW is also associatedwith venous thromboem-
bolism, a disease in which mechanism of hypercoagulability
and stasis are central players. Our results point toward a
modest and direct role of RDW in the development of
ischemic stroke, but not in the development of MI. Growing
evidence supports more pronounced roles for hypercoagul-
ability and stasis in the pathogenesis of ischemic stroke than
in the pathogenesis of MI. First, mechanisms related to
hypercoagulability, such as prothrombotic genotypes, are
reported to be more pronounced in ischemic stroke than in
MI.45 Second, approximately 40% of the ischemic strokes are
caused by cardioembolic events, in which stasis plays a
pivotal role in the pathogenesis.46
A major strength of our study is the prospective design
with a long follow-up time. Participants were recruited from
the general population with a high attendance rate. Few
cases were missed during follow-up due to the single hospi-
tal serving the Tromsø area, and the thorough process of case
identiﬁcation and validation. One limitation to the study is
the skewed age distribution due to the selected population
invited to the second visit of Tromsø 4, whichmay reduce the
generalizability of our ﬁndings. There was only one mea-
surement of hs-CRP and RDW throughout the study period,
which could result in an underestimation of the true asso-
ciations due to regression dilution bias.47 Another potential
weakness with only one measurement is the uncertainty of
whether increased hs-CRP levels could be due to a chronic or
an acute inﬂammatory process. To avoid this, all subjects
with hs-CRP >10 mg/L were excluded from our analyses, as
this indicates an ongoing acute-phase response.48
In conclusion, we found that the association between
RDW and arterial CVD was not confounded by hs-CRP, and
that RDW had a modest direct effect on the risk of ischemic
stroke, but not MI. Our study calls for a reassessment of
chronic inﬂammation as the main explanation for the asso-
ciation between RDW and arterial CVD. Future studies are
warranted to further explore other potentially underlying
mechanisms.
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